INFECT is based on a consortium consisting of 14 international partners, including clinicians, scientists, SMEs and a patient organization, that has joined forces to employ a new strategy to advance our understanding of the pathogenesis of necrotizing soft tissue infections (NSTIs); thereby improve identification and management of patients and promote novel developments in therapeutics and diagnostics of NSTIs.
Partner 1Karolinska Institutet (KI) ranks as one of the world’s leading medical universities, which today account for 40 percent of all medical research in Sweden.
Karolinska Institutet is responsible for Work Package (WP) 5, WP6 and WP9.
Key contributors to activities are: Anna Norrby-Teglund, Professor, PhD; Mattias Svensson, PhD; and Linda Johansson, PhD.
Partner 2Copenhagen University hospital, Rigshospitalet (RH), is a regional hospital for 1 million inhabitants and a hospital of reference for all types of highly specialized treatments in Denmark, Faeroe Islands and Greenland, totally 5.5 million inhabitants.
Rigshospitalet is responsible for WP2.
Key contributors to activities are: Ole Hyldegaard, MD, PhD, Erik C Jansen, MD, Dr. Med. Sci., Martin Bruun Madsen, MD, Diana Isaksen, research nurse.Team Leader
Ole Hyldegaard, MD, PhD.
Department of Anaesthesia, Head and Neck Surgery Centre
2100 Copenhagen, Denmark
Partner 3Stockholm County Council serves for the healthcare for its 2 million inhabitants in the region.
Karolinska university Hospital is one of the Swedish partners involved in WP2.
Key contributors to activities are: Michael Nekludov, MD.Team leader
Michael Nekludov, MD
Karolinska University Hospital, Stockholm, Sweden
Partner 4The Blekinge County Council Hospital in Karlskrona handles all trauma and acute medical care in Blekinge and is also referral centre for the Southeast region of Sweden (population 575 000) for hyperbaric medicine.
Partner 4 is one of the Swedish partners involved in WP2.
Key contributors to activities are: Ylva Karlsson, MD, Dag Benoni, MD.Team Leader
Ylva Karlsson, MD
Department of Anesthesiology and Intensive Care
Blekinge County Council Hospital
Karlskrona, S-37 185 Karlskrona, Sweden
Partner 5Sahlgrenska University Hospital (SU) provides emergency and basic care for the Göteborg region, and its 700,000 inhabitants.
Partner 5 is one of the Swedish partners involved in WP2.
Key contributors to activities are: Per Arnell MD, Anders Rosen MD, Joakim Trogen MD, Anders Rosemar MD, PhDTeam Leader
Per Arnell, MD
Sahlgrenska University Hospital
Rondvägen 5, 416 50, Gothenburg, Sweden
Partner 6University of Bergen (UiB) is the second largest university in Norway. The Faculty of Dentistry and Medicine holds 1000 employees and the faculty is responsible for the education of medical doctors, dentists, pharmacists and nutritionist.
Partner 6 is the Norwegian partner involved in WP2.
Key contributors to activities are: Steinar Skrede, MD, PhD; Trond Bruun, MD, Oddvar Oppegaard, MD, and Torbjørn Nedrebø, MD, PhD.Team Leader
Steinar Skrede, MD, PhD
Division for Infectious Diseases
Haukeland University Hospital
Jonas Liesvei 65, PB 1400, 5021 Bergen, Norway
Partner 8HZI is a multi-disciplinary research institute and has strong collaborative links with many academic and industrial research organizations worldwide.
Partner 8 is responsible for WP3.
Key contributors to activities are: Dr. Dietmar Pieper, Team leader; Dr. Andreas Itzek, PhD; Dr. Patric Nitsche-Schmitz, PhD; Anshu Babbar. Dr. Gursharan S Chhatwal (deceased) made indispensable contributions in the application phase and early phases of the project.Team Leader
Prof. Dietmar Pieper
Molecular Interactions and Processes
Helmholtz-Zentrum für Infektionsforschung GmbH
Inhoffenstraße 7, 38124 Braunschweig, Germany
Partner 9The Wageningen University & Research (WU-ATV), is an internationally leading education and research organization, and the largest in the Netherlands focusing on life sciences (non-medical).
Partner 9 is responsible for WP4.
Key contributors to activities are: Vítor Martins dos Santos, Professor; Jasper Jan Koehors, PhD; and Jesse Vandem, PhD.Team Leader
Professor Vítor Martins dos Santos
Laboratory of Systems and Synthetic Biology
Box 8033, 6700 EJ Wageningen, The Netherlands
Partner 10Université Lyon is a multidisciplinary university specializing in both fundamental and applied research and as such it can boast more than 4415 internationally published articles and 44 patents per year.
Partner 10 is the French partner involved in WP3.
Key contributor to activities are: Francois Vandenesh, Professor, MD, PhD.Team Leader
Professor Francois Vandenesch
Immunity Infection & Vaccination
Université Claude Bernard Lyon 1
INSERM Unit 1111, site Laennec, rue G. Paradin, 690008 Lyon
Partner 11LifeGlimmer GmbH is a newly established SME with the goal of providing to the Biotechnological, Biomedical and Environmental Research Communities an efficient way to outsource Scientific Computing needs.
Partner 11 is responsible for WP4.
Key contributors to activities are: Vítor Martins dos Santos.
Partner 13The Lee Spark NF Foundation, Necrotizing Fasciitis support and education, was established in 2000.
Partner 13 has its main role in WP8.
Key contributor to activities is: Doreen Marsden.
Partner 14Tel-Aviv University is one of largest and top research universities in Israel. The University’s Blavatnik School of Computer Science, is of international standard and acclamation.
Partner 14 is a partner involved in WP4.
Key contributor to activities is: Eytan Ruppin, Professor, MD, PhD.Team Leader
Professor Eytan Ruppin
Blavatnik School of Computer Science and School of Medicine
Tel Aviv University
Tel Aviv 69978, Israel
Partner 15The University of North Dakota (UND) is the state's oldest and largest University, with more than 15,000 students and 225 fields of study. UND is a Carnegie Doctoral Research Institution with an international reputation for research and scholarship, notably in health sciences, nutrition, energy and environmental protection, aerospace, and engineering. Although UND's research is felt around the world, it plays an important role in the emergence of North Dakota as a technological and economic leader.
Partner 15 is the American partner responsible for WP1.
Key contributors to Partner 15 activities are: Malak Kotb, Professor, PhD.Team Leader
Professor Malak Kotb
Department of Basic Sciences, School of Medicine and Health Sciences
University of North Dakota
Grand Forks, North Dakota, United States
Partner 16Cube Dx GmbH was founded in 2015 and is located in St. Valentin (Austria). The company focuses on the development, production and distribution of multiplex tests for in-vitro diagnostics in clinical practice. Multiplex diagnostics allow for the identification in parallel of a variety of significant parameters (bacteria, gene mutations, immune response, etc.) in a single test, requiring only a minimal amount of sample material.
Cube Dx has developed a complete and entirely new multiplex technology based on the principle of microarrays. The hybcell – the only cylindrical microarray available anywhere – delivers speedy and reliable results with minimal effort. The hyborg – a completely automated device – processes the samples fully independently and without any intervention by the user.
The Cube Dx assay is based on compact sequencing and compact profiling, and is designed to address especially those complex diagnostic challenges where fast answers are essential. In addition to the Early Pathogen Identification Cube Dx offers tests for Companion Diagnostics (oncology) as well as Monitoring of patients suffering with severe infections or inflammation.
Partner 16 is responsible for WP7.
Key contributors to activities are: Christoph Reschreiter, MSc, CEO, and Bernard Ronacher, CSO